Cervical Cancer | Topics

 
Pembrolizumab Combo Significantly Improved Survival for Persistent, Recurrent, or Metastatic Cervical Cancer
June 23, 2021

Merck’s press release announced positive data from the KEYNOTE-826 trial investigating pembrolizumab plus chemotherapy with or without bevacizumab for patients with cervical cancer.

FDA Grants Priority Review to Balstilimab for Cervical Cancer After Chemotherapy
June 17, 2021

The anti–PD-1 antibody is being assessed as therapy for patients with recurrent or metastatic cervical cancer after positive results indicate improved responses with the monotherapy.

Advanced Cervical Cancer Shows No Survival Benefit With Adjuvant Chemotherapy
June 04, 2021

Awaited outcomes of the phase 3 OUTBACK trial presented at the 2021 ASCO Annual Meeting do not indicate benefit of adjuvant chemotherapy for patients with cervical cancer.